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Abstract
Background: Bronchiectasis is a chronic respiratory condition. Persistent bacterial colonisation in the stable state
with increased and sometimes altered bacterial burden during exacerbations are accepted as key features in the
pathophysiology. The extent to which respiratory viruses are present during stable periods and in exacerbations is
less well understood.
Methods: This study aimed to determine the incidence of respiratory viruses within a cohort of bronchiectasis
patients with acute exacerbations at a teaching hospital and, separately, in a group of patients with stable
bronchiectasis. In the group of stable patients, a panel of respiratory viruses were assayed for using real time
quantitative PCR in respiratory secretions and exhaled breath. The Impact of virus detection on exacerbation rates
and development of symptomatic infection was evaluated.
Results: Routine hospital-based viral PCR testing was only requested in 28% of admissions for an exacerbation. In
our cohort of stable bronchiectasis patients, viruses were detected in 92% of patients during the winter season, and
33% of patients during the summer season. In the 2-month follow up period, 2 of 27 patients presented with an
exacerbation.
Conclusions: This pilot study demonstrated that respiratory viruses are commonly detected in patients with stable
bronchiectasis. They are frequently detected during asymptomatic viral periods, and multiple viruses are often
present concurrently.
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Background
Bronchiectasis is a progressive disease characterised by
permanent dilatation of bronchi, impairment of muco-
ciliary clearance, and retention of secretions. Recurrent
respiratory infections are a key feature of bronchiectasis,
with the majority of research focusing on the role of
bacteria in stable patients, during acute exacerbations
and particularly in disease progression [1, 2]. Despite
significant advances in diagnostic immunology and radi-
ology, and a growing global awareness of bronchiectasis
as a significant twenty-first century clinical problem, the
underlying cause of bronchiectasis in a given patient is
not always clear. Approximately 40% of cases remain
idiopathic [3], after the most common causes (immuno-
deficiencies, cystic fibrosis (CF), primary ciliary dysfunc-
tion (PCD), allergic bronchopulmonary aspergillosis
(ABPA), connective tissue disorders, chronic obstructive
pulmonary disease (COPD)-related, or asthma-related)
have been excluded [4, 5].
Respiratory infections in early childhood are an
important cause of airway damage with the potential to
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initiate the vicious cycle of epithelial damage, airway
dilatation, mucostasis, and bacterial colonisation [6].
Prior to widespread vaccination in the mid twentieth
century, measles and pertussis played a major role in
post-infectious damage leading to bronchiectasis [7].
The incidence and mortality of pneumonia associated
with influenza and pneumococcal infection has also been
reduced in both paediatric [8–10] and adult populations
with access to vaccination programs [11, 12]. Pneumonia
in childhood caused by common respiratory viruses has
been associated with significant early airway damage and
these viruses are emerging as major factors in the
subsequent development of bronchiectasis [4, 13]. While
research has focused on defining the aetiology of
bronchiectasis due to its implications in individualised
treatment and management of the disease, little work
has been done to define the role of respiratory viruses in
stable and acute bronchiectasis.
As there is considerable phenotypic overlap between
bronchiectasis, CF and COPD, the basic understanding
gained from investigating the role of viruses in exacerba-
tions and asymptomatic viral detection during stable
phases in these diseases may guide our knowledge
regarding bronchiectasis.
The association between viral infection and bacterial
superinfection is well described in the literature, and
more recently, with changes in the microbiome. In
COPD and CF, respiratory viruses precipate exacerba-
tions, which in turn, are associated with accelerated
disease progression [14]. Mallia et al. [15] demonstrated
that experimental rhinovirus infection in patients with
COPD could induce symptoms associated with exacer-
bations, and induce changes in the microbiota. These
findings in COPD have been further confirmed by a ser-
ial analysis of the lung microbiome following rhinovirus
infection [16]. In patients with CF, significantly higher
levels of respiratory viruses were detected during ex-
acerbations (46%) compared to stable phases (17%)
[17]. The detection of viruses during exacerbation has
also been associated with an increase in colony
counts of Pseudomonas aeruginosa, suggesting that
viruses may also affect the stability of the microbiome
in cystic fibrosis [18]. In these diseases, increased viral
presence was often observed during exacerbations which
also lead to changes in the resident microbial communi-
ties. Bacterial colonisation is a common and key feature of
the pathophysiology of bronchiectasis. Less is known
about the role of viruses in stable state bronchiectasis, or
the effect of viruses on the equilibrium between symbiotic
and pathogenic bacterial species.
Therefore, this pilot study aimed to determine the
incidence of respiratory virus testing ordered by physi-
cians within a cohort of bronchiectasis patients with
acute exacerbations at a teaching hospital and separately,
to determine the incidence of viral detection within a
group of patients with stable bronchiectasis to establish
baseline viral prevalence. The incidence of symptomatic




A retrospective clinical audit was undertaken to deter-
mine the rate of testing for respiratory viruses for pa-
tients admitted to Concord Repatriation General
Hospital July 2011 to June 2016 with an acute exacerba-
tion of bronchiectasis. Patient data regarding exacerba-
tion frequency, previous lung function and hospital




Two cohorts of patients were recruited from an
outpatient clinic whilst clinically stable. All patients
attending the specialised bronchiectasis clinic during the
recruitment months were asked to participate. Bronchi-
ectasis was deemed to be clinically stable from the point
of view by the consultant physician in clinic based on
the patient’s history, and no deterioration in clinical
symptoms in the month prior to their clinic visit. A
history of viral-related symptoms was not an exclusion
criteria. One cohort was recruited during the winter
months in Australia (May – September), while the other
was recruited during the summer months (January –
March). Samples were collected from each patient dur-
ing their clinic visit, to determine if viruses were present
within the lungs of bronchiectasis patients when clinic-
ally stable, similar to resident bacterial species. This is a
tertiary referral centre for PCD, where the diagnosis of
PCD was made based on ciliary motility studies and
electron microscopy. Patients provided a basic medical
history and filled out a common cold questionnaire at
the time of recruitment [19]. The common cold ques-
tionnaire (CCQ) assesses viral symptoms on an 11-point
scale. Based on the presence or absence of these symp-
toms, the questionnaire predicts the likelihood of a viral
infection. Results are classified into three categories; ‘no
virus’, ‘possible virus’ or ‘probable virus’ depending on
how many symptoms are reported [19]. The results of
the questionnaires were considered at the time of
analysis in conjunction with the viral PCR results, and
were not used as inclusion or exclusion criteria.
Spirometry was performed at the time of sample
collection (according to ATS/ERS guidelines) [20] and
compared to previous results to ensure that patients
were at baseline. FEV1 was used as a surrogate measure
of severity in this cohort of patients. The filters from the
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spirometer mouthpieces were frozen during storage,
then processed for RNA extraction from exhaled breath
using a methodology described previously [21], and
spontaneously expectorated sputum samples were also
collected. All patients were reviewed by the physiother-
apist in clinic if sputum was not easily spontaneously
expectorated.
To investigate if asymptomatic infections could
develop into acute exacerbations, information regarding
exacerbations and hospitalisations in the following
2 months were collected for all patients. Other patient
outcomes, including lung function, acute viral or bacter-
ial infections, were also collected.
Sample molecular processing
Filters and sputum samples were analysed for a panel of
respiratory viruses using PCR. Virus RNA was extracted
from the exhaled breath captured in spirometry filters
using a methodology published previously [21]. Filters
were first removed from the spirometry mouthpieces
and 1 ml of Bioline Lysis Buffer RLY (Bioline, Alexandria,
Australia) was then added. This was centrifuged for 2 min
at 10 000 rpm. The eluate was collected after the final spin
and stored at − 20 °C until RNA extraction. Sputum sam-
ples were homogenised by mixing the secretion with 1 ml
of 1% B-ME Lysis Buffer RLY to achieve a final volume of
1.5 ml, which was then stored at − 20 °C. Following this,
RNA was purified using the Isolate II RNA Mini Kit
(Bioline, Alexandria, Australia) before conversion to
cDNA using the Bioline SensiFAST cDNA Synthesis Kit
(Bioline, Alexandria, Australia).
cDNA was assayed by uniplex real time reverse tran-
scription polymerase chain reactions for human rhino-
virus (HRV), respiratory syncytial virus (RSV), influenza
virus type A and influenza virus type B, parainfluenza
virus (PIV) 1, 2 and 3, and human metapneumovirus
(HMPV). Real Time quantitative PCR (qPCR) assays
utilised the StepOnePlus Real-Time PCR System (Applied
Biosystems, ThermoFisher, Massachusetts, USA). All sam-
ples were run in triplicate, with 2 μl of cDNA template
added to Bioline SensiFAST Probe Hi-ROX Master Mix.
PCR primers were sourced from the literature [21–25],
and have been previously optimised using clinical samples.
Forward and reverse primers were added along with virus
specific probe. The qPCR was run for 40 cycles, and the
cycle threshold (CT) value was defined for each reaction.
Statistical analysis
T-tests were used to compare parametric data sets,
Mann-Whitney tests for non-parametric data, and Fisher’s
exact test was completed for contingency table analyses
using GraphPad Prism version 6.
Results
Part 1
During the study period 47 patients were identified from
the Bronchiectasis Registry as having been admitted to
Concord Repatriation General Hospital for an exacerba-
tion of bronchiectasis with a total of 83 admissions. The
average age for this cohort was 72 ± 14 years, mean ± SD
(range 24–88) (male = 19).
Of the 83 total admissions, viral PCR was requested in
only 23. In comparison, bacterial and fungal cultures
were requested in 73 admissions.
Viral PCR was positive in 9 of 23 cases (39%), with 3
cases of influenza A and 6 cases of HRV.
Bacterial and fungal cultures were positive in 22/73
admissions (30%). The most commonly detected pathogen
by culture was Pseudomonas aeruginosa in 9 admissions,
followed by Haemophilus influenzae in 7 cases, Burkhol-
deria cepacia in 1, and Achromobacter xylosoxidans in 1
case. Fungal species were less common, with Aspergillus
spp. detected during 3 exacerbations, and Candida albi-
cans in 1 case.
Part 2
Winter cohort
Twelve patients with stable bronchiectasis were re-
cruited in the winter cohort. The clinical characteristics
of these patients are summarised in Table 1. Four
patients were on maintenance therapy with an inhaled
corticosteroid (ICS) /long acting beta agonist (LABA)
combination inhaler, while the majority had been pre-
scribed a short acting beta agonist (SABA) as needed.
Only one patient reported being a past smoker, all other
patients had never smoked.
Of the 12 patients with bronchiectasis recruited during
the winter period, 9 of these also had a concurrent diag-
nosis of PCD. The majority of these patients (11/12) had
relatively preserved lung function with an FEV1 greater
than the lower limit of normal. One patient had severely
reduced lung function, with an FEV1 of only 21% pre-
dicted (0.56 L), and an FEV1/FVC ratio of 50% based on
ATS/ERS guidelines [26].
All patients completed the CCQ on the day of secre-
tion sampling. None reported enough symptoms on the
11-point scale to be categorised as “probable virus”. All
patients remained stable, with no reported exacerbations
or hospital admissions within a month prior to or 2
months after sample collection.
Filters and sputum samples were processed for a panel
of respiratory viruses. Nine of 12 patients had respiratory
virus RNA identified in filter samples. In the filters,
influenza was the most commonly detected respiratory
virus (9/12), with 3 patients having influenza A, 3 with
influenza B, 2 with concurrent influenza A and B detec-
tion and one patient who demonstrated co-detection of
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human rhinovirus and influenza A (Table 2). Using
qPCR, in the samples where the same virus was detected
in the filter as the sputum sample, the CT value was
lower (approximately 33 cycles) compared with those
viruses found in the sputum alone (approximately
37 cycles).
In sputum samples, 11 of 12 patients had a respiratory
virus identified. A single patient had only influenza A
identified. Co-infection was more common with 7 pa-
tients showing concurrent detection of HRV, RSV, influ-
enza A and B; 1 patient with HRV, RSV and influenza A;
1 with HRV and RSV; 1 with HRV and influenza A. All 9
subjects with virus detected in exhaled breath also had
virus detected in the matched sputum sample. As 11 of
12 patients in the winter cohort were viral positive, it
was not possible to correlate virus detection with disease
severity based on FEV1. Similarly, a correlation between
viral detection and use of SABA, or ICS/LABA combin-
ation treatment could not be deduced.
Summer cohort
Fifteen patients were recruited in the summer cohort.
Their clinical characteristics are summarised in Table 1.
Ten patients were on maintenance therapy with an ICS/
LABA combination inhaler, two had additional tiotro-
pium therapy; 12/15 had been prescribed a SABA PRN.
All patients reported never smoking.
In this cohort, 3 of 15 patients had a concomitant
PCD diagnosis, while 2 of 15 also had a diagnosis of
asthma. This was a slightly more severe cohort of bron-
chiectasis patients based on spirometry when compared
with the group recruited during the winter season. The
mean FEV1 in this group was 59% of predicted, however
this was not significantly different to the winter group.
Only one patient reported symptoms of viral infection at
the time of sample collection, the rest of the patients re-
ported feeling well at the time of their clinic visit which
was confirmed by responses to the common cold
questionnaire. Two patients with severe bronchiectasis
(one with comorbid asthma) were subsequently admitted
to hospital for an exacerbation within 2 months of sam-
ple collection.
During the summer season, respiratory viruses were
less commonly detected, with 3 of 15 patients demon-
strating influenza A detection in the filters and 5 of 15
samples detecting Influenza A in the sputum sample
(Table 2). No other respiratory viruses on our panel were
detected in these samples. Furthermore, none of the pa-
tients in the summer cohort had a “probable virus”
based on the CCQ. In the patients who were viral posi-
tive in the summer cohort, the average FEV1 was lower


















Winter (n = 12) 36 ± 12 10/2 77% ± 22% 9/12 (75%) 11/12 (92%) 10/12 (83%) 10/12 (83%) 0/12 (0%)
Summer (n = 15) 60 ± 17 12/3 60% ± 33% 3/15 (20%) 5/15 (33%) 5/15 (33%) 0/15 (0%) 1/15 (7%)
Overall (n = 27) 49 ± 19 22/5 67% ± 29% 12/27 (44%) 16/27 (59%) 15/27 (56%) 10/27 (37%) 1/27 (4%)
Table 2 Specific viruses detected in the filter and sputum
samples of patients in Summer and Winter cohorts
Patient Winter
Filter positive Sputum positive
1 Flu A RV, RSV, Flu A + B
2 Flu B RV, RSV, Flu A + B
3 Flu B RV, RSV, Flu A + B
4 Flu B RV, RSV, Flu A + B
5 Flu A RV, RSV + Flu A
6 RV + RSV
7 Flu A
8 RV + Flu A RV + Flu A
9 Flu A + B RV, RSV, Flu A + B
10 Flu A + B RV, RSV, Flu A + B
11 Flu A RV, RSV, Flu A + B
12
Patient Summer
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(p > 0.05), compared with the viral negative group. How-
ever, no associations between medication usage and viral
detection were observed.
One patient was admitted to hospital within 2 weeks
of the clinic visit with an exacerbation of bronchiectasis,
and influenza A was again detected in both exhaled
breath and sputum samples. Another patient who expe-
rienced an exacerbation 6 weeks after their clinic visit,
did not have any viruses detected in either sample.
Comparison of cohorts
There was a significant difference in viral detection
between Summer and Winter cohorts (p < 0.01), with a
greater rate of viral detection observed during the winter
months (Fig. 1). These cohorts were not age or severity
matched, and there was a significantly higher rate of
underlying PCD in the winter cohort (p < 0.05).
Discussion
Our small retrospective audit of admissions for exacer-
bation of bronchiectasis revealed how infrequently viral
PCR testing was requested in a large teaching hospital
with ready access to on site rapid respiratory viral PCR.
Reflecting the current state of the literature, bacterial
and fungal species were more frequently assumed to be
the etiological agents and therefore, tested for in the ma-
jority of patients presenting with an exacerbation. Viral
PCR testing was only requested in 28% of the bronchiec-
tasis exacerbations included in the audit, compared with
88% of admissions where bacterial and fungal culture
were requested.
However, despite the greater frequency of request for
bacterial and fungal culture, viruses were still detected
in 39% of the samples when viral PCR was requested,
compared with bacterial or fungal pathogen detection in
30% of samples sent for testing. It is important that
sampling rates increase, and prospective, longitudinal
studies of both bacterial and viral pathogens in stable
and exacerbating bronchiectasis are undertaken, if we
are to understand with more precision, the role of
viruses in exacerbations and their seasonality.
Due to the low rate of viral testing in acute exacerba-
tions of bronchiectasis at our centre, we designed a
study to determine the incidence of respiratory virus
detection during stable periods and whether this was
associated with an increased risk of exacerbation or
developing a symptomatic viral infection. Studying stable
patients with bronchiectasis provides information re-
garding the background level of viruses to inform future
analysis of results obtained during acute exacerbations.
Our pilot study demonstrated that respiratory viruses
are commonly detected in respiratory secretions and the
exhaled breath of patients with stable bronchiectasis.
They are frequently detected during asymptomatic pe-
riods, and multiple viruses are often present concurrently.
In this study, there was a 92% detection rate in the
winter cohort, and a 33% detection rate in the summer
cohort. Other studies have detection rates of around 20%
in stable bronchiectasis rising to around 40–50% in exac-
erbations in non-CF bronchiectasis in adults [27, 28]. One
potential reason for obtaining such high virus detection by
PCR is contamination within the PCR reaction. We are
confident that high viral detection rates in the winter
cohort this is not caused by poor PCR technique or
experimental contamination as out negative controls were
always negative. Furthermore, whilst the samples were
collected during different periods of the year, the PCRs
were carried out simultaneously. However, we used a
highly sensitive PCR which can detect as few as 5 virions.
In our study, even low CT values were classified as viral
positive whereas in other studies these might be classified
as negative. Whist not a part of this study, we have com-
pared our research lab virus PCR results to virus positivity
by PCR obtained from a diagnostic lab. We found almost
100% agreement for all viruses, apart from rhinovirus,
where we found our PCR was more sensitive (twice the
detection frequency). We think that the most plausible
explanation for the high sample detection in our winter
cohort happened to be sampled during a year that was
recognised to have a heavy burden of influenza infections.
Other possible reasons might be the increased severity of
bronchiectasis based on FEV1 values in our cohort, and
Fig. 1 Rates of single or multiple respiratory virus detection during stable state in the summer and winter cohorts
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also, the high incidence of PCD as our clinic is a state-
wide referral centre for PCD. However, it is unusual to
have found such high rates of multiple virus detection,
and further studies are needed in PCD to confirm these
findings. There is currently little literature regarding the
detection and persistence of respiratory viruses in the
respiratory tract of individuals with PCD.
Respiratory viruses were more common during
winter season, compared with the summer season.
This study confirms previously reported seasonality of
respiratory viruses [29] for RSV, however rhinovirus
has been shown to occur all year round in respiratory
specimens which was not observed in this cross-
sectional study of bronchiectasis patients. Influenza
has also demonstrated peak detection during the win-
ter months in temperate zones, and year-round distri-
bution in tropical areas [30]. In this study, we
observed a heavy burden of influenza during the
winter season, however influenza A virus was still
detected in multiple asymptomatic individuals during
the summer months.
Detection of respiratory viruses in the exhaled breath
and sputum samples of this bronchiectasis cohort, was
not significantly associated with disease severity or risk
of exacerbation within the 2 month follow up period. In
the one patient who was admitted to hospital with a
bronchiectasis exacerbation within 2 weeks of their
clinic visit, influenza A was present within both the ex-
haled breath and sputum sample. However, this was the
only case where an exacerbation was associated with
virus detection in our study. The short duration of this
follow up time may not be adequate, however, to make a
clear determination of exacerbation risk in this cohort.
A longitudinal study design with regular viral sampling
during periods of both stable disease and exacerbation,
and more in depth analysis of patient outcomes may be
needed to elucidate this risk.
No association was observed between viral detection
and treatment with ICS/LABA or SABA alone. In the
summer cohort, viruses were more commonly detected
in patients with more severe disease as indicated by
spirometry, with 80% patients who had influenza A de-
tection demonstrating an FEV1 below 30% predicted
based on the GLI-2012 reference set [31]. In the winter
cohort, viral detection had no significant association
with spirometry values.
Real time PCR allowed quantification of viral load,
with higher viral load detection in the sputum sample
predicting detection in the exhaled breath sample
collected using the spirometry filters. Huang et al. [32]
showed that presence of influenza virus within the
respiratory tract is necessary but not sufficient to cause
a symptomatic influenza infection. Host immune
responses play an important role, and activation of
multiple simultaneous pattern recognition receptors to
cause antiviral and inflammatory responses are associ-
ated with symptomatic infection. Individuals who retain
tight control over these responses usually remain asymp-
tomatic, and may explain why asymptomatic infection
was so prevalent in our cohort. These patients with
bronchiectasis all have chronic bacterial lung colonisa-
tion, which may play a role in downregulating immune
responses [33].
A surprising finding was that of influenza A detection
only during the summer months. Traditionally, influenza
A activity peaks during the winter months and viruses
such as rhinovirus are more commonly seen in summer
and early autumn. The Australian influenza surveillance
network showed that there was a higher than normal
level of influenza A detected during January to March of
2017, the sampling period of our summer cohort. Likely
due to the fact that this group of bronchiectasis patients
have an underlying respiratory disease, and impaired
muco-ciliary clearance, it is possible that these individ-
uals were more susceptible to acquiring these circulating
viruses.
A large proportion of those recruited during the win-
ter months had PCD as the underlying cause of bronchi-
ectasis, as this study was undertaken at a tertiary referral
centre for PCD. Ciliary dysmotility impairs mucociliary
clearance and it seems plausible that this might result in
persistence of viral nucleic acids within sputum, even if
the virus is not actively replicating. Whilst the number
of subjects in this pilot is small, it raises the possibility
that differences in underlying pathophysiology of bron-
chiectasis extend to heterogeneity in the pathogenesis of
viruses.
Since the introduction of culture-independent tech-
niques, a substantial increase in bacterial detection
has been observed [34]. Molecular methods that iden-
tify bacterial species based on nucleic acid presence
has greatly improved diagnostic accuracy [35, 36], and
has allowed discovery of a whole range of bacterial
species that are present within the lower respiratory
tract. The introduction of these molecular based
methods such as PCR, have also allowed the detection
of respiratory viral species to become faster and eas-
ier [37]. This greatly increased the rate of respiratory
infections that were found to be attributable to vi-
ruses, as this is a much more sensitive and specific
tool. This was an important step in realising the high
frequency of respiratory viral infections, and thus
their importance in clinical disease. It also allowed a
more guided approach to treatment, with a decrease
in the use of antibacterial agents in some cases. Char-
acterising the role of viruses in both stable bronchiec-
tasis and during exacerbations may allow a greater
understanding of disease pathogenesis.
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Conclusions
Our pilot study provides preliminary data supporting
the notion that respiratory viruses are an important
part of the lung microbiome in patients with bronchi-
ectasis. The high rates of respiratory virus detection
in patients with stable bronchiectasis encourages
further studies in this area to determine how viruses
may impact both chronic and transient bacterial
species within the lung, and the role that viruses may
have in exacerbations. This is the first study to inves-
tigate the potential impact of viruses in bronchiec-
tasis. Many fundamental questions have been raised
regarding the role of respiratory viruses in this
disease process, and as outlined, recent advances in
metagenomic techniques have provided the tools to
investigate this area. We are just beginning to under-
stand the role of viruses in many chronic respiratory
diseases and it is now timely to apply this work in
patients with bronchiectasis.
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